{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T04:22:07Z","timestamp":1776831727366,"version":"3.51.2"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2018,9,21]],"date-time":"2018-09-21T00:00:00Z","timestamp":1537488000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oncogene"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1038\/s41388-018-0508-5","type":"journal-article","created":{"date-parts":[[2018,9,21]],"date-time":"2018-09-21T08:31:56Z","timestamp":1537518716000},"page":"1200-1210","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["LMTK3 is essential for oncogenic KIT expression in KIT-mutant GIST and melanoma"],"prefix":"10.1038","volume":"38","author":[{"given":"Lillian R.","family":"Klug","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amber E.","family":"Bannon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathalie","family":"Javidi-Sharifi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ajia","family":"Town","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William H.","family":"Fleming","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Judy K.","family":"VanSlyke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linda S.","family":"Musil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan A.","family":"Fletcher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey W.","family":"Tyner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael C.","family":"Heinrich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,9,21]]},"reference":[{"key":"508_CR1","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/0092-8674(90)90280-R","volume":"63","author":"ON Witte","year":"1990","unstructured":"Witte ON. Steel locus defines new multipotent growth factor. Cell. 1990;63:5\u20136.","journal-title":"Cell"},{"key":"508_CR2","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1002\/j.1460-2075.1991.tb07993.x","volume":"10","author":"S Lev","year":"1991","unstructured":"Lev S, Givol D, Yarden Y. A specific combination of substrates is involved in signal transduction by the kit-encoded receptor. EMBO J. 1991;10:647\u201354.","journal-title":"EMBO J"},{"key":"508_CR3","doi-asserted-by":"crossref","first-page":"15970","DOI":"10.1016\/S0021-9258(19)49629-4","volume":"267","author":"S Lev","year":"1992","unstructured":"Lev S, Yarden Y, Givol D. Dimerization and activation of the kit receptor by monovalent and bivalent binding of the stem cell factor. J Biol Chem. 1992;267:15970\u20137.","journal-title":"J Biol Chem"},{"key":"508_CR4","first-page":"11970","volume":"8","author":"N Kajimoto","year":"2015","unstructured":"Kajimoto N, Nakai N, Ohkouchi M, Hashikura Y, Liu-Kimura NN, Isozaki K, et al. Characterization of various types of mast cells derived from model mice of familial gastrointestinal stromal tumors with KIT-Asp818Tyr mutation. Int J Clin Exp Pathol. 2015;8:11970\u201382.","journal-title":"Int J Clin Exp Pathol"},{"key":"508_CR5","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1002\/path.2296","volume":"214","author":"N Nakai","year":"2008","unstructured":"Nakai N, Ishikawa T, Nishitani A, Liu NN, Shincho M, Hao H, et al. A mouse model of a human multiple GIST family with KIT-Asp820Tyr mutation generated by a knock-in strategy. J Pathol. 2008;214:302\u201311.","journal-title":"J Pathol"},{"key":"508_CR6","doi-asserted-by":"publisher","first-page":"6631","DOI":"10.1158\/0008-5472.CAN-05-0891","volume":"65","author":"BP Rubin","year":"2005","unstructured":"Rubin BP, Antonescu CR, Scott-Browne JP, Comstock ML, Gu Y, Tanas MR, et al. A knock-in mouse model of gastrointestinal stromal tumor harboring kit K641E. Cancer Res. 2005;65:6631\u20139.","journal-title":"Cancer Res"},{"key":"508_CR7","doi-asserted-by":"publisher","first-page":"6821","DOI":"10.1158\/1078-0432.CCR-08-0575","volume":"14","author":"C Beadling","year":"2008","unstructured":"Beadling C, Jacobson-Dunlop E, Hodi FS, Le C, Warrick A, Patterson J, et al. KIT gene mutations and copy number in melanoma subtypes. Clin Cancer Res. 2008;14:6821\u20138.","journal-title":"Clin Cancer Res"},{"key":"508_CR8","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/S0002-9440(10)63120-3","volume":"164","author":"K Kemmer","year":"2004","unstructured":"Kemmer K, Corless CL, Fletcher JA, McGreevey L, Haley A, Griffith D, et al. KIT mutations are common in testicular seminomas. Am J Pathol. 2004;164:305\u201313.","journal-title":"Am J Pathol"},{"key":"508_CR9","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1080\/10428190400007565","volume":"46","author":"L Larizza","year":"2005","unstructured":"Larizza L, Magnani I, Beghini A. The Kasumi-1 cell line: a t(8;21)-kit mutant model for acute myeloid leukemia. Leuk & Lymphoma. 2005;46:247\u201355.","journal-title":"Leuk & Lymphoma"},{"key":"508_CR10","doi-asserted-by":"publisher","first-page":"10560","DOI":"10.1073\/pnas.92.23.10560","volume":"92","author":"H Nagata","year":"1995","unstructured":"Nagata H, Worobec AS, Oh CK, Chowdhury BA, Tannenbaum S, Suzuki Y, et al. Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder. Proc Natl Acad Sci USA. 1995;92:10560\u20134.","journal-title":"Proc Natl Acad Sci USA"},{"key":"508_CR11","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1016\/S0002-9440(10)65419-3","volume":"154","author":"Q Tian","year":"1999","unstructured":"Tian Q, Frierson HF Jr., Krystal GW, Moskaluk CA. Activating c-kit gene mutations in human germ cell tumors. Am J Pathol. 1999;154:1643\u20137.","journal-title":"Am J Pathol"},{"key":"508_CR12","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1038\/nrc3143","volume":"11","author":"CL Corless","year":"2011","unstructured":"Corless CL, Barnett CM, Heinrich MC. Gastrointestinal stromal tumours: origin and molecular oncology. Nat Rev Cancer. 2011;11:865\u201378.","journal-title":"Nat Rev Cancer"},{"key":"508_CR13","doi-asserted-by":"publisher","first-page":"3182","DOI":"10.1200\/JCO.2012.47.7836","volume":"31","author":"FS Hodi","year":"2013","unstructured":"Hodi FS, Corless CL, Giobbie-Hurder A, Fletcher JA, Zhu M, Marino-Enriquez A, et al. Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin. J Clin Oncol. 2013;31:3182\u201390.","journal-title":"J Clin Oncol"},{"key":"508_CR14","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1053\/hupa.2002.124122","volume":"33","author":"RP Dematteo","year":"2002","unstructured":"Dematteo RP, Heinrich MC, El-Rifai WM, Demetri G. Clinical management of gastrointestinal stromal tumors: before and after STI-571. Hum Pathol. 2002;33:466\u201377.","journal-title":"Hum Pathol"},{"key":"508_CR15","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1007\/978-3-319-22539-5_13","volume":"167","author":"KR Spencer","year":"2016","unstructured":"Spencer KR, Mehnert JM. Mucosal Melanoma: Epidemiology, Biology and Treatment. Cancer Treat Res. 2016;167:295\u2013320.","journal-title":"Cancer Treat Res"},{"key":"508_CR16","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1200\/JCO.2007.13.4403","volume":"26","author":"CD Blanke","year":"2008","unstructured":"Blanke CD, Demetri GD, von Mehren M, Heinrich MC, Eisenberg B, Fletcher JA, et al. Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J Clin Oncol. 2008;26:620\u20135.","journal-title":"J Clin Oncol"},{"key":"508_CR17","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1200\/JCO.2007.13.4452","volume":"26","author":"CD Blanke","year":"2008","unstructured":"Blanke CD, Rankin C, Demetri GD, Ryan CW, von Mehren M, Benjamin RS, et al. Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J Clin Oncol. 2008;26:626\u201332.","journal-title":"J Clin Oncol"},{"key":"508_CR18","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1016\/S0140-6736(04)17098-0","volume":"364","author":"J Verweij","year":"2004","unstructured":"Verweij J, Casali PG, Zalcberg J, LeCesne A, Reichardt P, Blay JY, et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet. 2004;364:1127\u201334.","journal-title":"Lancet"},{"key":"508_CR19","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1081\/CNV-120002485","volume":"20","author":"JH Edmonson","year":"2002","unstructured":"Edmonson JH, Marks RS, Buckner JC, Mahoney MR. Contrast of response to dacarbazine, mitomycin, doxorubicin, and cisplatin (DMAP) plus GM-CSF between patients with advanced malignant gastrointestinal stromal tumors and patients with other advanced leiomyosarcomas. Cancer Invest. 2002;20:605\u201312.","journal-title":"Cancer Invest"},{"key":"508_CR20","doi-asserted-by":"publisher","first-page":"2289","DOI":"10.1158\/1078-0432.CCR-14-1630","volume":"21","author":"RD Carvajal","year":"2015","unstructured":"Carvajal RD, Lawrence DP, Weber JS, Gajewski TF, Gonzalez R, Lutzky J, et al. Phase II study of nilotinib in melanoma harboring KIT alterations following progression to prior KIT inhibition. Clin Cancer Res. 2015;21:2289\u201396.","journal-title":"Clin Cancer Res"},{"key":"508_CR21","doi-asserted-by":"publisher","first-page":"2904","DOI":"10.1200\/JCO.2010.33.9275","volume":"29","author":"J Guo","year":"2011","unstructured":"Guo J, Si L, Kong Y, Flaherty KT, Xu X, Zhu Y, et al. Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification. J Clin Oncol. 2011;29:2904\u20139.","journal-title":"J Clin Oncol"},{"key":"508_CR22","doi-asserted-by":"publisher","first-page":"2046","DOI":"10.1200\/JCO.2007.14.0707","volume":"26","author":"FS Hodi","year":"2008","unstructured":"Hodi FS, Friedlander P, Corless CL, Heinrich MC, Mac Rae S, Kruse A, et al. Major response to imatinib mesylate in KIT-mutated melanoma. J Clin Oncol. 2008;26:2046\u201351.","journal-title":"J Clin Oncol"},{"key":"508_CR23","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1056\/NEJMoa020461","volume":"347","author":"GD Demetri","year":"2002","unstructured":"Demetri GD, von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, Roberts PJ, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med. 2002;347:472\u201380.","journal-title":"N Engl J Med"},{"key":"508_CR24","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1080\/14737159.2017.1308826","volume":"17","author":"AE Bannon","year":"2017","unstructured":"Bannon AE, Klug LR, Corless CL, Heinrich MC. Using molecular diagnostic testing to personalize the treatment of patients with gastrointestinal stromal tumors. Expert Rev Mol Diagn. 2017;17:445\u201357.","journal-title":"Expert Rev Mol Diagn."},{"key":"508_CR25","doi-asserted-by":"publisher","first-page":"7510","DOI":"10.1158\/1078-0432.CCR-09-0190","volume":"15","author":"AW Gramza","year":"2009","unstructured":"Gramza AW, Corless CL, Heinrich MC. Resistance to tyrosine kinase inhibitors in gastrointestinal stromal tumors. Clin Cancer Res. 2009;15:7510\u20138.","journal-title":"Clin Cancer Res"},{"key":"508_CR26","doi-asserted-by":"publisher","first-page":"4182","DOI":"10.1158\/1078-0432.CCR-04-2245","volume":"11","author":"CR Antonescu","year":"2005","unstructured":"Antonescu CR, Besmer P, Guo T, Arkun K, Hom G, Koryotowski B, et al. Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation. Clin Cancer Res. 2005;11:4182\u201390.","journal-title":"Clin Cancer Res"},{"key":"508_CR27","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1002\/path.2382","volume":"216","author":"B Liegl","year":"2008","unstructured":"Liegl B, Kepten I, Le C, Zhu M, Demetri GD, Heinrich MC, et al. Heterogeneity of kinase inhibitor resistance mechanisms in GIST. J Pathol. 2008;216:64\u201374.","journal-title":"J Pathol"},{"key":"508_CR28","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1158\/1535-7163.MCT-06-0641","volume":"6","author":"KG Roberts","year":"2007","unstructured":"Roberts KG, Odell AF, Byrnes EM, Baleato RM, Griffith R, Lyons AB, et al. Resistance to c-KIT kinase inhibitors conferred by V654A mutation. Mol Cancer Ther. 2007;6:1159\u201366.","journal-title":"Mol Cancer Ther"},{"key":"508_CR29","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/S1368-7646(03)00062-1","volume":"6","author":"E Weisberg","year":"2003","unstructured":"Weisberg E, Griffin JD. Resistance to imatinib (Glivec): update on clinical mechanisms. Drug Resist Update: Rev Comment Antimicrob Anticancer Chemother. 2003;6:231\u20138.","journal-title":"Drug Resist Update: Rev Comment Antimicrob Anticancer Chemother"},{"key":"508_CR30","doi-asserted-by":"publisher","first-page":"2238","DOI":"10.1182\/blood-2007-06-097253","volume":"111","author":"JW Tyner","year":"2008","unstructured":"Tyner JW, Walters DK, Willis SG, Luttropp M, Oost J, Loriaux M, et al. RNAi screening of the tyrosine kinome identifies therapeutic targets in acute myeloid leukemia. Blood. 2008;111:2238\u201345.","journal-title":"Blood"},{"key":"508_CR31","doi-asserted-by":"publisher","first-page":"8695","DOI":"10.1073\/pnas.0903233106","volume":"106","author":"JW Tyner","year":"2009","unstructured":"Tyner JW, Deininger MW, Loriaux MM, Chang BH, Gotlib JR, Willis SG, et al. RNAi screen for rapid therapeutic target identification in leukemia patients. Proc Natl Acad Sci USA. 2009;106:8695\u20138700.","journal-title":"Proc Natl Acad Sci USA"},{"key":"508_CR32","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1016\/j.neuroscience.2007.05.048","volume":"148","author":"M Tomomura","year":"2007","unstructured":"Tomomura M, Morita N, Yoshikawa F, Konishi A, Akiyama H, Furuichi T, et al. Structural and functional analysis of the apoptosis-associated tyrosine kinase (AATYK) family. Neuroscience. 2007;148:510\u201321.","journal-title":"Neuroscience"},{"key":"508_CR33","doi-asserted-by":"publisher","first-page":"49605","DOI":"10.1074\/jbc.M209335200","volume":"277","author":"H Wang","year":"2002","unstructured":"Wang H, Brautigan DL. A novel transmembrane Ser\/Thr kinase complexes with protein phosphatase-1 and inhibitor-2. J Biol Chem. 2002;277:49605\u201312.","journal-title":"J Biol Chem"},{"key":"508_CR34","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1038\/nm.2351","volume":"17","author":"G Giamas","year":"2011","unstructured":"Giamas G, Filipovic A, Jacob J, Messier W, Zhang H, Yang D, et al. Kinome screening for regulators of the estrogen receptor identifies LMTK3 as a new therapeutic target in breast cancer. Nat Med. 2011;17:715\u20139.","journal-title":"Nat Med"},{"key":"508_CR35","doi-asserted-by":"publisher","first-page":"3371","DOI":"10.1038\/onc.2012.343","volume":"32","author":"J Stebbing","year":"2013","unstructured":"Stebbing J, Filipovic A, Lit LC, Blighe K, Grothey A, Xu Y, et al. LMTK3 is implicated in endocrine resistance via multiple signaling pathways. Oncogene. 2013;32:3371\u201380.","journal-title":"Oncogene"},{"key":"508_CR36","doi-asserted-by":"publisher","first-page":"ra58","DOI":"10.1126\/scisignal.2005170","volume":"7","author":"Y Xu","year":"2014","unstructured":"Xu Y, Zhang H, Lit LC, Grothey A, Athanasiadou M, Kiritsi M, et al. The kinase LMTK3 promotes invasion in breast cancer through GRB2-mediated induction of integrin beta(1). Sci Signal. 2014;7:ra58.","journal-title":"Sci Signal"},{"key":"508_CR37","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1016\/j.celrep.2015.06.073","volume":"12","author":"Y Xu","year":"2015","unstructured":"Xu Y, Zhang H, Nguyen VT, Angelopoulos N, Nunes J, Reid A, et al. LMTK3 represses tumor suppressor-like genes through chromatin remodeling in breast cancer. Cell Rep. 2015;12:837\u201349.","journal-title":"Cell Rep"},{"key":"508_CR38","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1158\/0008-5472.CAN-14-0573","volume":"75","author":"N Javidi-Sharifi","year":"2015","unstructured":"Javidi-Sharifi N, Traer E, Martinez J, Gupta A, Taguchi T, Dunlap J, et al. Crosstalk between KIT and FGFR3 promotes gastrointestinal stromal tumor cell growth and drug resistance. Cancer Res. 2015;75:880\u201391.","journal-title":"Cancer Res"},{"key":"508_CR39","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1038\/labinvest.3780461","volume":"82","author":"T Taguchi","year":"2002","unstructured":"Taguchi T, Sonobe H, Toyonaga S, Yamasaki I, Shuin T, Takano A, et al. Conventional and molecular cytogenetic characterization of a new human cell line, GIST-T1, established from gastrointestinal stromal tumor. Lab Invest. 2002;82:663\u20135.","journal-title":"Lab Invest"},{"key":"508_CR40","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/978-1-4939-6337-9_7","volume":"1470","author":"A Agarwal","year":"2016","unstructured":"Agarwal A, Tyner JW. RNAi screening of leukemia cells using electroporation. Methods Mol Biol. 2016;1470:85\u201394.","journal-title":"Methods Mol Biol"},{"key":"508_CR41","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1158\/1541-7786.MCR-10-0065","volume":"8","author":"F Rossi","year":"2010","unstructured":"Rossi F, Yozgat Y, de Stanchina E, Veach D, Clarkson B, Manova K, et al. Imatinib upregulates compensatory integrin signaling in a mouse model of gastrointestinal stromal tumor and is more effective when combined with dasatinib. Mol Cancer Res. 2010;8:1271\u201383.","journal-title":"Mol Cancer Res"},{"key":"508_CR42","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1158\/1535-7163.MCT-08-0884","volume":"8","author":"K Sakurama","year":"2009","unstructured":"Sakurama K, Noma K, Takaoka M, Tomono Y, Watanabe N, Hatakeyama S, et al. Inhibition of focal adhesion kinase as a potential therapeutic strategy for imatinib-resistant gastrointestinal stromal tumor. Mol Cancer Ther. 2009;8:127\u201334.","journal-title":"Mol Cancer Ther"},{"key":"508_CR43","first-page":"2737","volume":"133","author":"T Takahashi","year":"2013","unstructured":"Takahashi T, Serada S, Ako M, Fujimoto M, Miyazaki Y, Nakatsuka R, et al. New findings of kinase switching in gastrointestinal stromal tumor under imatinib using phosphoproteomic analysis. Int J Cancer. 2013;133:2737\u201343.","journal-title":"Int J Cancer"},{"key":"508_CR44","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.canlet.2015.12.026","volume":"372","author":"J Jacob","year":"2016","unstructured":"Jacob J, Favicchio R, Karimian N, Mehrabi M, Harding V, Castellano L, et al. LMTK3 escapes tumour suppressor miRNAs via sequestration of DDX5. Cancer Lett. 2016;372:137\u201346.","journal-title":"Cancer Lett"},{"key":"508_CR45","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s40164-016-0060-3","volume":"5","author":"N An","year":"2016","unstructured":"An N, Cen B, Cai H, Song JH, Kraft A, Kang Y. Pim1 kinase regulates c-Kit gene translation. Exp Hematol Oncol. 2016;5:31.","journal-title":"Exp Hematol Oncol"},{"key":"508_CR46","doi-asserted-by":"publisher","first-page":"3891","DOI":"10.1158\/0008-5472.CAN-12-0026","volume":"72","author":"M Grzmil","year":"2012","unstructured":"Grzmil M, Hemmings BA. Translation regulation as a therapeutic target in cancer. Cancer Res. 2012;72:3891\u20133900.","journal-title":"Cancer Res"},{"key":"508_CR47","doi-asserted-by":"publisher","first-page":"5745","DOI":"10.1158\/1078-0432.CCR-14-1397","volume":"20","author":"AP Garner","year":"2014","unstructured":"Garner AP, Gozgit JM, Anjum R, Vodala S, Schrock A, Zhou T, et al. Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients. Clin Cancer Res. 2014;20:5745\u201355.","journal-title":"Clin Cancer Res"},{"key":"508_CR48","doi-asserted-by":"publisher","first-page":"C1809","DOI":"10.1152\/ajpcell.00580.2006","volume":"292","author":"KB Gagnon","year":"2007","unstructured":"Gagnon KB, England R, Diehl L, Delpire E. Apoptosis-associated tyrosine kinase scaffolding of protein phosphatase 1 and SPAK reveals a novel pathway for Na-K-2C1 cotransporter regulation. Am J Physiol Cell Physiol. 2007;292:C1809\u20131815.","journal-title":"Am J Physiol Cell Physiol"}],"container-title":["Oncogene"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41388-018-0508-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41388-018-0508-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41388-018-0508-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:13:51Z","timestamp":1684617231000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41388-018-0508-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,21]]},"references-count":48,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2019,2]]}},"alternative-id":["508"],"URL":"https:\/\/doi.org\/10.1038\/s41388-018-0508-5","relation":{},"ISSN":["0950-9232","1476-5594"],"issn-type":[{"value":"0950-9232","type":"print"},{"value":"1476-5594","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9,21]]},"assertion":[{"value":"13 March 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 August 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 August 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 September 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"MCH is a consultant for Novartis, Deciphera Pharmaceuticals, Blueprint Medicines, Ariad Pharmaceuticals, Bayer Pharmaceuticals, and Molecular MD. MCH has provided expert testimony and has a patent licensed to Novartis. MCH receives research support from Ariad, Deciphera, Blueprint Medicines and has equity interest in Molecular MD. JWT receives research support from Agios Pharmaceuticals, Array Biopharma, Aptose Biosciences, AstraZeneca, Constellation Pharmaceuticals, Genentech, Gilead, Incyte Corporation, Janssen Pharmaceutica, Seattle Genetics, Syros, Takeda Pharmaceutical Company and is a consultant for Leap Oncology.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}